Exploring the development path of the world’s largest generic drug consumer country to identify a way forward for China’s generic drug industry

The expiration of patents on globally blockbuster innovative drugs has led to a steady influx of generic drugs onto the market, causing a sharp decline in original-brand drug sales—a phenomenon dubbed the 'patent cliff.' It is estimated that between 2018 and 2022, $159 billion worth of original-brand drug patents will expire, resulting in $82 billion in losses for innovator pharmaceutical companies. These companies may choose to exit the market entirely or reduce production, thereby creating a rapid opportunity for generics to capture market share. The Development Path of the U.S. Generic Drug Industry In the early 20th century, U.S. drug approval required no proof of safety or efficacy. Following a medical incident involving the anti-inflammatory drug sulfanilamide in 1938, all drugs seeking market entry were required to submit publicly available literature demonstrating safety and file applications with the FDA. Prior to World War II, the U.S. pharmaceutical market was largely dominated by European manufacturers; however, wartime demand spurred the gradual emergence of the domestic generic drug industry. In 1961, the globally marketed drug thalidomide caused over ten thousand infant birth defects. As a result, after 1962, both new and generic drugs were required to provide data proving safety and efficacy. Moreover, generic drugs could only be developed after all patents on the original-brand drug had fully expired. The requirement to generate safety and efficacy data extended time-to-market and incurred high clinical research costs—slowing generic drug industry development. By 1983, only 35% of expired-patent original-brand drugs faced corresponding generic competition, capturing just 13% of market share—contributing to persistently high drug prices. Starting in 1984, the U.S. adopted the Abbreviated New Drug Application (ANDA) pathway, substituting bioequivalence studies for full clinical trials and permitting generic drug development to begin before the original-brand drug’s patent expiry. This significantly reduced the time and cost required for generic drug R&D and commercialization. Thereafter, the U.S. generic drug industry entered a period of rapid growth: the share of generics among prescription drugs rose from ~10% in the early 1980s to 86% in 2013. In 2016, generics accounted for 90% of prescriptions but only 20% of total drug sales revenue, while patented drugs accounted for 10% of prescriptions but 80% of sales revenue. The streamlining of generic drug approvals dampened incentives for novel drug R&D. To balance interests between innovator and generic drug firms, the U.S. Congress simultaneously introduced the patent linkage system, comprising provisions such as patent term extension, data exclusivity, research exemption, and the 180-day exclusivity period for successful patent challenges. The 180-day exclusivity period grants the first applicant to successfully challenge a patent an exclusive marketing window during which the FDA will not approve any other generic versions. This allows the first-to-file generic to seize market share ahead of competitors and earn substantial profits. For example, in 2001, Barr Pharmaceuticals successfully challenged Prozac—the top-selling drug that year with $2.4 billion in sales—and captured 82% of its market share within six months, generating $250 million in profit. Between 1995 and 2012, the proportion of newly approved drugs facing patent challenges rose from 9% to 82%. Among drugs with annual sales exceeding $1 billion, the challenge rate reached 91%, and the average interval between patent issuance and challenge shortened from 18.7 to 6.9 years. The introduction of this exclusivity period dramatically accelerated the substitution of generics for original-brand drugs. After patent expiry, original-brand drugs rapidly lose market share to generics—and the pace of displacement continues to accelerate. For original-brand drugs whose patents expired in 1999–2000, the innovator retained ~70% market share two months after the first generic launched. In contrast, for drugs whose patents expired in 2011–2012, the innovator held only ~30% market share two months post-launch and just 20% after ten months.

Operating profit surges 557%, yet why did SK Hynix still fall?

SK Hynix posted record-breaking figures across three key metrics—but its stock plunged over 15% intraday, triggering a circuit breaker. The underlying reasons lie in two critical issues: long-term contract pricing for HBM memory and the shipment timeline for HBM4—here’s the breakdown. On July 29, SK Hynix released its Q2 results: revenue stood at KRW 79.3187 trillion (+257% YoY); operating profit reached KRW 60.5426 trillion (+557% YoY); and operating margin hit 76%. Revenue, operating profit, and net profit—all set quarterly records. Yet on the same day, Seoul’s stock market responded with a sharp sell-off: the share price fell over 15% intraday, triggering a circuit breaker, and market capitalization dropped below KRW 1,000 trillion for the first time in roughly three months. Record-breaking financials triggered circuit-breaker-level selling. The numbers are solid—but expectations were even higher. The market isn’t dismissing the results; rather, it had already priced in performance beyond actuals. The consensus forecast from 22 Korean brokerage firms exceeded actual results by about 5%; LSEG SmartEstimate projected operating profit at approximately KRW 64 trillion—also above the reported figure. A 5% shortfall isn’t dramatic in itself—but what amplified its impact was the extreme concentration of forecasts. According to The Korea Economic Daily’s synthesis of broker views, the coefficient of variation among the 22 brokers’ forecasts stood at just 4–5%, indicating near-unanimous agreement on the same number. With expectations so tightly clustered, even a minor miss left no room for error or cushion. The quarter with the steepest price hikes—and yet, SK Hynix didn’t fully capitalize. Q2 memory markets were seller-dominated: spot prices for mainstream DRAM rose 37% QoQ, and NAND prices surged 55% QoQ. Yet SK Hynix’s average DRAM selling price rose only ~30% QoQ—underperforming the broader market. The reason lies in pricing mechanisms. According to Kim Won-joon, memory analyst at Korea Investment & Securities (name transliterated), SK Hynix’s HBM sales account for a larger share of its portfolio than those of competitors. Since HBM is governed by long-term agreements with limited price elasticity, SK Hynix’s blended average selling price lagged behind the market during a quarter when general-memory prices soared. The company itself acknowledged on its earnings call: “Timing of product shipments and product mix composition in Q2 impacted our overall blended average selling price.” SK Hynix has signed long-term supply agreements (LTAs) with around 10 customers—including core clients—with typical contract durations of about five years. These contracts include volume commitments, deposit requirements, and variable pricing mechanisms. Such contracts serve as a moat during downturns—guaranteeing both volume and minimum pricing—but become a ceiling during upswings: while spot prices skyrocket, contracted customers continue purchasing at fixed contract rates. The result is paradoxical: companies with higher HBM exposure exhibit lower earnings elasticity during price-up cycles. Kim Won-joon projects that starting in 2027, long-term contract pricing will fully reflect prevailing market conditions, allowing HBM average selling prices to rise again. He maintains a “Buy” rating and a target price of KRW 3.8 million. Two interpretations of HBM4 The second issue concerns HBM4. The company’s official statement: mass production and initial shipments began in Q2; ramp-up will accelerate in H2, and products have met customer-specified operational speed requirements. The stated timeline appears unproblematic. However, pre-earnings reports told a different story: multiple sources indicated that mass production timing had been delayed from end-Q2 to Q3—aligning with the slower-than-expected ramp-up of NVIDIA’s Rubin platform. Digitimes, citing ZDNet Korea, reported that SK Hynix is considering cutting its 2026 HBM4 shipments to NVIDIA by approximately 20–30%.

Quarterly Sales and Profit Set Records at Balchem; Sales Reached $290.7 Million

Oct 23, 2026

Balchem Corporation reported record third-quarter 2026 financial results, with net sales increasing 8.6% year-over-year to $290.7 million. GAAP net earnings rose 16.0% to $46.7 million, supported by growth across all three reporting segments.

Stock Titan

2026-03-22

BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms

2026-03-27

Balchem Reports €0.0 Million NonCurrent Deferred Revenue as of December 2025

2026-04-09

Balchem Corp. Stock Valuation Revised Amid Competitive FMCG Landscape

2026-04-11

Balchem Reports $581 Million Gross Property, Plant and Equipment as of December 2025

2026-04-16

Zinc Methionine Chelates Market Forecast Report 2025-2033 Featuring Alltech, Balchem, Titan Biotech, UNO VETCHEM, Zinpro, Chaitanya Biologicals, Chengdu Chelation Biology, JH, Novus, Priya